JP2008537547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008537547A5 JP2008537547A5 JP2008502896A JP2008502896A JP2008537547A5 JP 2008537547 A5 JP2008537547 A5 JP 2008537547A5 JP 2008502896 A JP2008502896 A JP 2008502896A JP 2008502896 A JP2008502896 A JP 2008502896A JP 2008537547 A5 JP2008537547 A5 JP 2008537547A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- phenyl
- methyl
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 51
- 239000001257 hydrogen Substances 0.000 claims 51
- -1 phenylsulfonylamino Chemical group 0.000 claims 49
- 150000002431 hydrogen Chemical class 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 18
- 125000001153 fluoro group Chemical group F* 0.000 claims 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 15
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000004414 alkyl thio group Chemical group 0.000 claims 10
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 8
- 125000001246 bromo group Chemical group Br* 0.000 claims 8
- 125000002346 iodo group Chemical group I* 0.000 claims 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 3
- YPDOLVWKPFGIBB-QGZVFWFLSA-N 3-(4-tert-butylphenyl)-n-[(1r)-1-[4-(methanesulfonamido)phenyl]ethyl]-2-methylprop-2-enamide Chemical compound N([C@H](C)C=1C=CC(NS(C)(=O)=O)=CC=1)C(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 YPDOLVWKPFGIBB-QGZVFWFLSA-N 0.000 claims 2
- WCGYTMNVBCVJLH-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[3-fluoro-4-(methanesulfonamido)phenyl]methyl]-2-methylprop-2-enamide Chemical compound C=1C=C(NS(C)(=O)=O)C(F)=CC=1CNC(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 WCGYTMNVBCVJLH-UHFFFAOYSA-N 0.000 claims 2
- XCWKFLJPCLZFPY-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[3-fluoro-4-(methanesulfonamido)phenyl]methyl]but-2-enamide Chemical compound C=1C=C(C(C)(C)C)C=CC=1C(C)=CC(=O)NCC1=CC=C(NS(C)(=O)=O)C(F)=C1 XCWKFLJPCLZFPY-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- ZDOJKAWETLKRAR-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)C Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)C ZDOJKAWETLKRAR-UHFFFAOYSA-N 0.000 claims 2
- MVQZGMUKEVRCRJ-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1C)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1C)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl MVQZGMUKEVRCRJ-UHFFFAOYSA-N 0.000 claims 2
- IPPITQAIEDIDAN-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC IPPITQAIEDIDAN-UHFFFAOYSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 102000011040 TRPV Cation Channels Human genes 0.000 claims 2
- 108010062740 TRPV Cation Channels Proteins 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 2
- FSYKSFRXUZLDLC-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[1-[3-fluoro-4-(methanesulfonamido)phenyl]ethyl]-2-methylprop-2-enamide Chemical compound C=1C=C(NS(C)(=O)=O)C(F)=CC=1C(C)NC(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 FSYKSFRXUZLDLC-UHFFFAOYSA-N 0.000 claims 1
- SAXIEWTXPPNTPQ-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[2,5-difluoro-4-(methanesulfonamido)phenyl]methyl]prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C=CC(=O)NCC1=CC(F)=C(NS(C)(=O)=O)C=C1F SAXIEWTXPPNTPQ-UHFFFAOYSA-N 0.000 claims 1
- XSUQVHTVTDENPS-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[3-fluoro-4-(methanesulfonamido)-5-methylphenyl]methyl]prop-2-enamide Chemical compound FC1=C(NS(C)(=O)=O)C(C)=CC(CNC(=O)C=CC=2C=CC(=CC=2)C(C)(C)C)=C1 XSUQVHTVTDENPS-UHFFFAOYSA-N 0.000 claims 1
- KVWPNZFSUHALEX-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[4-(methanesulfonamido)-3-methylphenyl]methyl]prop-2-enamide Chemical compound C1=C(NS(C)(=O)=O)C(C)=CC(CNC(=O)C=CC=2C=CC(=CC=2)C(C)(C)C)=C1 KVWPNZFSUHALEX-UHFFFAOYSA-N 0.000 claims 1
- GOPCVYDNMNVXLB-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[4-(methanesulfonamido)phenyl]methyl]-2-methylprop-2-enamide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CNC(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 GOPCVYDNMNVXLB-UHFFFAOYSA-N 0.000 claims 1
- MKZOQDDEBSOPHS-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=C(C=C(C(=C2)I)NS(=O)(=O)C)Cl Chemical compound CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=C(C=C(C(=C2)I)NS(=O)(=O)C)Cl MKZOQDDEBSOPHS-UHFFFAOYSA-N 0.000 claims 1
- HFONNRJJPMYDHW-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C(=C2)I)NS(=O)(=O)C)F Chemical compound CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C(=C2)I)NS(=O)(=O)C)F HFONNRJJPMYDHW-UHFFFAOYSA-N 0.000 claims 1
- CUDYMAHPCXNGGH-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C=C2)NS(=O)(=O)C)[N+](=O)[O-] Chemical compound CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C=C2)NS(=O)(=O)C)[N+](=O)[O-] CUDYMAHPCXNGGH-UHFFFAOYSA-N 0.000 claims 1
- CSRODXZWTLGCED-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CN(C)C(=O)NC2=CC(=C(C=C2F)NS(=O)(=O)C)F Chemical compound CC(C)(C)C1=CC=C(C=C1)CN(C)C(=O)NC2=CC(=C(C=C2F)NS(=O)(=O)C)F CSRODXZWTLGCED-UHFFFAOYSA-N 0.000 claims 1
- YXKHKFLLTRQGFW-UHFFFAOYSA-N CC(C=C(C)C(=O)N)C1=CC(=C(C=C1)NS(=O)(=O)C)F Chemical compound CC(C=C(C)C(=O)N)C1=CC(=C(C=C1)NS(=O)(=O)C)F YXKHKFLLTRQGFW-UHFFFAOYSA-N 0.000 claims 1
- RJQSGDYBJRGRGO-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C(=C1)Cl)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC Chemical compound CS(=O)(=O)NC1=C(C=C(C(=C1)Cl)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC RJQSGDYBJRGRGO-UHFFFAOYSA-N 0.000 claims 1
- NZMRNRBISIEWGR-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)I Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)I NZMRNRBISIEWGR-UHFFFAOYSA-N 0.000 claims 1
- UZPJCAWQGSECJM-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl UZPJCAWQGSECJM-UHFFFAOYSA-N 0.000 claims 1
- YRSRONNGLWKBEN-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)F Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)F YRSRONNGLWKBEN-UHFFFAOYSA-N 0.000 claims 1
- ZQGAWNADNXEOET-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)F Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)F ZQGAWNADNXEOET-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 206010037083 Prurigo Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2005-0022986 | 2005-03-19 | ||
| KR20050022986 | 2005-03-19 | ||
| US66326905P | 2005-03-21 | 2005-03-21 | |
| US60/663,269 | 2005-03-21 | ||
| PCT/KR2006/000988 WO2006101321A1 (en) | 2005-03-19 | 2006-03-17 | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008537547A JP2008537547A (ja) | 2008-09-18 |
| JP2008537547A5 true JP2008537547A5 (https=) | 2009-04-16 |
| JP5064374B2 JP5064374B2 (ja) | 2012-10-31 |
Family
ID=37023953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502895A Expired - Fee Related JP5159604B2 (ja) | 2005-03-19 | 2006-03-15 | バニロイド受容体拮抗薬としての新規な化合物、その異性体又はその薬剤学的に許容される塩、及びこれを含む医薬組成物 |
| JP2008502896A Expired - Fee Related JP5064374B2 (ja) | 2005-03-19 | 2006-03-17 | バニロイド受容体拮抗薬としての新規な化合物、その異性体またはその薬剤学的に許容される塩、及びこれを含む医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502895A Expired - Fee Related JP5159604B2 (ja) | 2005-03-19 | 2006-03-15 | バニロイド受容体拮抗薬としての新規な化合物、その異性体又はその薬剤学的に許容される塩、及びこれを含む医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7763657B2 (https=) |
| EP (2) | EP1861357B1 (https=) |
| JP (2) | JP5159604B2 (https=) |
| KR (2) | KR101304981B1 (https=) |
| AR (2) | AR053561A1 (https=) |
| AU (2) | AU2006225496A1 (https=) |
| BR (2) | BRPI0608714A2 (https=) |
| CA (2) | CA2601871A1 (https=) |
| EA (2) | EA200702020A1 (https=) |
| IL (2) | IL185891A0 (https=) |
| MX (2) | MX2007011466A (https=) |
| NO (2) | NO20075353L (https=) |
| TW (2) | TW200716523A (https=) |
| WO (2) | WO2006101318A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101304981B1 (ko) * | 2005-03-19 | 2013-09-06 | (주)아모레퍼시픽 | 바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 |
| PL2054411T3 (pl) | 2006-07-27 | 2015-02-27 | Amorepacific Corp | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20110160279A1 (en) * | 2007-08-13 | 2011-06-30 | Board Of Trustees Of Southern Illinois University | METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA |
| US8557872B2 (en) | 2008-01-28 | 2013-10-15 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| WO2009136625A1 (ja) * | 2008-05-07 | 2009-11-12 | 大日本住友製薬株式会社 | 環状アミン－１－カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
| US8691855B2 (en) | 2008-07-02 | 2014-04-08 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same |
| CN103429242A (zh) * | 2010-11-03 | 2013-12-04 | 夏威夷大学 | 用于预防和治疗心脏肥大的方法和组合物 |
| AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| ES2643403T3 (es) | 2011-12-28 | 2017-11-22 | Global Blood Therapeutics, Inc. | Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| HK1214587A1 (en) * | 2012-12-28 | 2016-07-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Cinnamamide derivative |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| WO2014150258A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| MX379235B (es) | 2013-03-15 | 2025-03-11 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
| CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| SG11201804647TA (en) | 2015-12-04 | 2018-06-28 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6087254A (ja) * | 1983-10-19 | 1985-05-16 | Japan Carlit Co Ltd:The | 新規尿素化合物及びそれを含有する除草剤 |
| HK1042472B (zh) * | 1999-02-22 | 2005-12-09 | Medifron Dbt Co., Ltd. | 作爲有效的香草类受体激动剂和镇痛药的含有树脂毒素药效基团的香草类类似物，其组合物以及应用 |
| ATE328868T1 (de) | 2000-08-21 | 2006-06-15 | Pacific Corp | Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten |
| AU2001280229B2 (en) | 2000-08-21 | 2006-12-07 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| GB0105895D0 (en) * | 2001-03-09 | 2001-04-25 | Smithkline Beecham Plc | Novel compounds |
| MXPA04005427A (es) | 2001-12-10 | 2005-04-19 | Amgen Inc | Ligandos de receptor vainilloide y su uso en tratamientos. |
| BR0309940A (pt) * | 2002-05-08 | 2005-02-09 | Bayer Healthcare Ag | Derivados de hidróxi-tetraidro-naftaleniluréia |
| AU2003251828A1 (en) * | 2002-07-12 | 2004-02-02 | Janssen Pharmaceutica N.V. | Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor |
| KR100707123B1 (ko) * | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
| KR101042490B1 (ko) * | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제 |
| ITMI20042042A1 (it) * | 2004-10-26 | 2005-01-26 | Pharmeste Srl | Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1 |
| ES2331153T3 (es) * | 2005-03-10 | 2009-12-22 | Pfizer Inc. | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. |
| KR101304981B1 (ko) | 2005-03-19 | 2013-09-06 | (주)아모레퍼시픽 | 바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 |
-
2006
- 2006-03-15 KR KR1020077024002A patent/KR101304981B1/ko not_active Expired - Fee Related
- 2006-03-15 JP JP2008502895A patent/JP5159604B2/ja not_active Expired - Fee Related
- 2006-03-15 BR BRPI0608714-0A patent/BRPI0608714A2/pt not_active Application Discontinuation
- 2006-03-15 US US11/909,136 patent/US7763657B2/en active Active
- 2006-03-15 EA EA200702020A patent/EA200702020A1/ru unknown
- 2006-03-15 EP EP06716379.0A patent/EP1861357B1/en not_active Expired - Lifetime
- 2006-03-15 MX MX2007011466A patent/MX2007011466A/es not_active Application Discontinuation
- 2006-03-15 AU AU2006225496A patent/AU2006225496A1/en not_active Abandoned
- 2006-03-15 WO PCT/KR2006/000929 patent/WO2006101318A1/en not_active Ceased
- 2006-03-15 CA CA002601871A patent/CA2601871A1/en not_active Abandoned
- 2006-03-17 TW TW095109337A patent/TW200716523A/zh unknown
- 2006-03-17 CA CA002601873A patent/CA2601873A1/en not_active Abandoned
- 2006-03-17 WO PCT/KR2006/000988 patent/WO2006101321A1/en not_active Ceased
- 2006-03-17 US US11/909,144 patent/US7960584B2/en active Active
- 2006-03-17 EP EP06716438A patent/EP1861358A4/en not_active Withdrawn
- 2006-03-17 AR ARP060101059A patent/AR053561A1/es unknown
- 2006-03-17 KR KR1020077024004A patent/KR101304979B1/ko not_active Expired - Fee Related
- 2006-03-17 TW TW095109137A patent/TW200716522A/zh unknown
- 2006-03-17 MX MX2007011205A patent/MX2007011205A/es not_active Application Discontinuation
- 2006-03-17 EA EA200702021A patent/EA200702021A1/ru unknown
- 2006-03-17 BR BRPI0608624-1A patent/BRPI0608624A2/pt not_active Application Discontinuation
- 2006-03-17 AU AU2006225434A patent/AU2006225434A1/en not_active Abandoned
- 2006-03-17 JP JP2008502896A patent/JP5064374B2/ja not_active Expired - Fee Related
- 2006-03-17 AR ARP060101058A patent/AR056943A1/es unknown
-
2007
- 2007-09-11 IL IL185891A patent/IL185891A0/en unknown
- 2007-09-11 IL IL185892A patent/IL185892A0/en unknown
- 2007-10-18 NO NO20075353A patent/NO20075353L/no not_active Application Discontinuation
- 2007-10-18 NO NO20075354A patent/NO20075354L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008537547A5 (https=) | ||
| JP2004517087A5 (https=) | ||
| JP2011529037A5 (https=) | ||
| JP2019504898A5 (https=) | ||
| JPWO2023106310A5 (https=) | ||
| RU2009119290A (ru) | Производные гидантоина, используемые в качестве ингибиторов ммр | |
| JP2006077019A5 (https=) | ||
| JP2011500658A5 (https=) | ||
| JP2017214387A5 (https=) | ||
| JP2011519854A5 (https=) | ||
| JP2014502979A5 (https=) | ||
| JP2013521286A5 (https=) | ||
| JP2010523476A5 (https=) | ||
| JP2008516968A5 (https=) | ||
| IL287159B2 (en) | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use | |
| JP2023143940A5 (https=) | ||
| HRP20150049T1 (hr) | Derivati oksazolil-metiletera kao agonisti alx-receptora | |
| JP2017522348A5 (https=) | ||
| JP2008538109A5 (https=) | ||
| JP2009501745A5 (https=) | ||
| JP2017509611A5 (https=) | ||
| JP2014518212A5 (ja) | 化合物及び組成物 | |
| JP2012501334A5 (https=) | ||
| RU2015105603A (ru) | Антагонисты минералокортикоидных рецепторов | |
| RU2008149936A (ru) | (2r)-2-[(4-сульфонил)аминофенил]пропанамиды и содержащие их фармацевтические композиции |